The evolution of kidney tumours

Some very interesting work has been coming out of the Francis Crick Institute in London about the evolution of kidney tumours. The research is being led by Dr Samra Turajlic who also works at the Royal Marsden Hospital in London and is one of KCSN’s trustees. Here is her explanation of this very exciting work: […]

read more

Cells from the centre of tumours are most likely to spread around the body

Research published in the journal Nature Ecology and Evolution led by scientists from the Francis Crick Institute, Royal Marsden, University College London and Cruces University Hospital has found that cells from different parts of kidney tumours behave differently. The researchers have discovered that cells from the centre of a kidney cancer tumour are the most […]

read more

Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]

read more

Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival

A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]

read more

The impact of sex and age on distribution of metastases in patients with kidney cancer

A recent study published in the International Journal of Clinical Oncology looked at the distribution of metastases in patients with metastatic renal cell carcinoma (RCC) according to age and sex. 9,607 patients with metastatic RCC were identified from the National Inpatient Sample database (2008-2015) and analysed for site of metastases according to age and sex. […]

read more

Obesity diminishes response to immunotherapy in kidney cancer

In this study, the researchers looked at the interaction between obesity and outcomes in patients taking immune checkpoint inhibitors (anti-PD-1 immunotherapy, e.g. nivolumab, pembrolizumab) for the treatment of renal cell carcinoma (RCC). Seventy-two (72) patients with metastatic RCC were treated with anti–PD-1 immunotherapy (none had been treated with immunotherapy before). Obese patients had poorer progression-free […]

read more

Individualising first line treatment for advanced kidney cancer

In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]

read more

Liquid biopsies in kidney cancer

In this review, the key substances found in the blood, such as circulating free (cf)DNA, cfRNA, proteins, and exosomes (sacs containing proteins, DNA and/or RNA), which may act as biomarkers for monitoring the progression of clear cell renal cell carcinoma (ccRCC) are discussed. Limitations of these techniques and promising technologies that could help with the […]

read more

Outcomes of complete metastasectomy in metastastic kidney cancer

A recent study from Canada investigated the use of surgery to remove metastases (metastasectomy)  as part of the treatment of metastatic renal cell carcinoma (RCC) and whether this delayed progression of the disease and improved survival. Real world data from 229 Canadian patients was used in this study. These data were matched with 803 control […]

read more

Patterns of initial metastatic recurrence after surgery for high-risk kidney cancer patients

This study looked at where metastases occurred after surgery for high-risk non-metastatic renal cell carcinoma (RCC). The study also identified the factors that indicated outcomes for these patients. A total of 1,057 patients with stage T3a or greater RCC were treated with surgery. 160 patients (59.3%) had one site of initial metastatic recurrence, while 110 […]

read more
Showing 1 to 10 of 46 results
  TOP